Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Recurrent Malignant Glioma

MedGen UID:: 1646561
•Concept ID:: C4684861
•: Neoplastic Process

Synonyms:

Recurrent High Grade Glioma; Recurrent High-Grade Glioma

Definition

The reemergence of malignant glioma after a period of remission. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVRecurrent Malignant Glioma

Neoplasm
- Malignant neoplastic disease
  - Malignant neoplasm of nervous system
    - Malignant neoplasm of the central nervous system
      - Glioma
        Malignant glioma
        Recurrent Malignant Glioma
        Recurrent Diffuse Intrinsic Pontine Glioma
        Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
        Recurrent Glioblastoma
        Recurrent Childhood Glioblastoma
        Recurrent Childhood Giant Cell Glioblastoma
        Recurrent Childhood Gliosarcoma
        Recurrent Giant Cell Glioblastoma
        Recurrent Gliosarcoma
        Recurrent Small Cell Glioblastoma
        Recurrent Supratentorial Glioblastoma
        Recurrent WHO Grade 3 Glioma
        Recurrent Anaplastic Astrocytoma
        Recurrent Childhood Anaplastic Astrocytoma
        Recurrent Anaplastic Ependymoma
        Recurrent Anaplastic Oligoastrocytoma
        Recurrent Childhood Anaplastic Oligoastrocytoma
        Recurrent Anaplastic Oligodendroglioma
        Recurrent Childhood Anaplastic Oligodendroglioma
        Recurrent Anaplastic Pleomorphic Xanthoastrocytoma

Professional guidelines

PubMed

Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.

Yao H, Liu J, Zhang C, Shao Y, Li X, Feng M, Wang X, Gan W, Zhou Y, Huang Y
J Clin Neurosci 2021 Aug;90:82-88. Epub 2021 Jun 5 doi: 10.1016/j.jocn.2021.05.032. PMID: 34275586

Management of recurrent malignant glioma--neurosurgical strategies.

Kostron H, Bauer R
Wien Med Wochenschr 2011 Jan;161(1-2):20-1. doi: 10.1007/s10354-010-0861-7. PMID: 21312095

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ
Lancet Oncol 2008 May;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6. PMID: 18452856

See all (37)

Recent clinical studies

Etiology

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.

Motoo N, Hayashi Y, Shimizu A, Ura M, Nishikawa R
Jpn J Clin Oncol 2019 Dec 18;49(11):1016-1023. doi: 10.1093/jjco/hyz125. PMID: 31665343 Free PMC Article

Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy for Recurrent Malignant Gliomas: A Systematic Review and Meta-analysis.

Hu YJ, Chen D, Zhang LF, Chen J
World Neurosurg 2019 Jul;127:176-185. Epub 2019 Apr 6 doi: 10.1016/j.wneu.2019.03.297. PMID: 30959254

Patterns of re-irradiation for recurrent gliomas and validation of a prognostic score.

Post CCB, Kramer MCA, Smid EJ, van der Weide HL, Kleynen CE, Heesters MAAM, Verhoeff JJC
Radiother Oncol 2019 Jan;130:156-163. Epub 2018 Nov 13 doi: 10.1016/j.radonc.2018.10.034. PMID: 30446315

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J
J Clin Oncol 2018 May 10;36(14):1419-1427. Epub 2018 Feb 12 doi: 10.1200/JCO.2017.75.8219. PMID: 29432077 Free PMC Article

Therapeutic strategies for local recurrent malignant glioma.

Sills AK Jr, Duntsch C, Weimar J
Curr Treat Options Oncol 2004 Dec;5(6):491-7. doi: 10.1007/s11864-004-0037-z. PMID: 15509482

See all (133)

Diagnosis

Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma.

Furuse M, Kawabata S, Wanibuchi M, Shiba H, Takeuchi K, Kondo N, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake SI
Jpn J Clin Oncol 2022 May 5;52(5):433-440. doi: 10.1093/jjco/hyac004. PMID: 35079791

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.

Motoo N, Hayashi Y, Shimizu A, Ura M, Nishikawa R
Jpn J Clin Oncol 2019 Dec 18;49(11):1016-1023. doi: 10.1093/jjco/hyz125. PMID: 31665343 Free PMC Article

Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.

Philbrick BD, Adamson DC
Expert Opin Investig Drugs 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. PMID: 30676111

Primetime for antiangiogenic therapy.

Tabatabai G, Stupp R
Curr Opin Neurol 2009 Dec;22(6):639-44. doi: 10.1097/WCO.0b013e328332ba28. PMID: 19786873

Therapeutic strategies for local recurrent malignant glioma.

Sills AK Jr, Duntsch C, Weimar J
Curr Treat Options Oncol 2004 Dec;5(6):491-7. doi: 10.1007/s11864-004-0037-z. PMID: 15509482

See all (92)

Therapy

Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma.

Furuse M, Kawabata S, Wanibuchi M, Shiba H, Takeuchi K, Kondo N, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake SI
Jpn J Clin Oncol 2022 May 5;52(5):433-440. doi: 10.1093/jjco/hyac004. PMID: 35079791

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

Therapeutic options for recurrent malignant glioma.

Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C
Radiother Oncol 2011 Jan;98(1):1-14. Epub 2010 Dec 13 doi: 10.1016/j.radonc.2010.11.006. PMID: 21159396

Primetime for antiangiogenic therapy.

Tabatabai G, Stupp R
Curr Opin Neurol 2009 Dec;22(6):639-44. doi: 10.1097/WCO.0b013e328332ba28. PMID: 19786873

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN
Curr Pharm Des 2007;13(35):3545-58. doi: 10.2174/138161207782794130. PMID: 18220791

See all (283)

Prognosis

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.

Motoo N, Hayashi Y, Shimizu A, Ura M, Nishikawa R
Jpn J Clin Oncol 2019 Dec 18;49(11):1016-1023. doi: 10.1093/jjco/hyz125. PMID: 31665343 Free PMC Article

Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.

Philbrick BD, Adamson DC
Expert Opin Investig Drugs 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. PMID: 30676111

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

Management of recurrent malignant glioma--neurosurgical strategies.

Kostron H, Bauer R
Wien Med Wochenschr 2011 Jan;161(1-2):20-1. doi: 10.1007/s10354-010-0861-7. PMID: 21312095

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN
Curr Pharm Des 2007;13(35):3545-58. doi: 10.2174/138161207782794130. PMID: 18220791

See all (147)

Clinical prediction guides

Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study.

Motoo N, Hayashi Y, Shimizu A, Ura M, Nishikawa R
Jpn J Clin Oncol 2019 Dec 18;49(11):1016-1023. doi: 10.1093/jjco/hyz125. PMID: 31665343 Free PMC Article

Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.

Philbrick BD, Adamson DC
Expert Opin Investig Drugs 2019 Mar;28(3):207-216. doi: 10.1080/13543784.2019.1572112. PMID: 30676111

Primetime for antiangiogenic therapy.

Tabatabai G, Stupp R
Curr Opin Neurol 2009 Dec;22(6):639-44. doi: 10.1097/WCO.0b013e328332ba28. PMID: 19786873

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN
Curr Pharm Des 2007;13(35):3545-58. doi: 10.2174/138161207782794130. PMID: 18220791

Temozolomide for recurrent high-grade glioma.

Macdonald DR
Semin Oncol 2001 Aug;28(4 Suppl 13):3-12. doi: 10.1016/s0093-7754(01)90065-x. PMID: 11550133

See all (138)

Recent systematic reviews

Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.

Cho SJ, Kim HS, Suh CH, Park JE
Korean J Radiol 2020 Jul;21(7):908-918. doi: 10.3348/kjr.2019.0898. PMID: 32524791 Free PMC Article

Hypofractionated stereotactic radiotherapy combined with chemotherapy or not in the management of recurrent malignant gliomas: A systematic review and meta-analysis.

Hu YJ, Zhang LF, Ding C, Chen D, Chen J
Clin Neurol Neurosurg 2019 Aug;183:105401. Epub 2019 Jun 25 doi: 10.1016/j.clineuro.2019.105401. PMID: 31260910

Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy for Recurrent Malignant Gliomas: A Systematic Review and Meta-analysis.

Hu YJ, Chen D, Zhang LF, Chen J
World Neurosurg 2019 Jul;127:176-185. Epub 2019 Apr 6 doi: 10.1016/j.wneu.2019.03.297. PMID: 30959254

Perfusion MRI as the predictive/prognostic and pharmacodynamic biomarkers in recurrent malignant glioma treated with bevacizumab: a systematic review and a time-to-event meta-analysis.

Choi SH, Jung SC, Kim KW, Lee JY, Choi Y, Park SH, Kim HS
J Neurooncol 2016 Jun;128(2):185-94. Epub 2016 Apr 23 doi: 10.1007/s11060-016-2102-4. PMID: 27108275

A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.

Dinnes J, Cave C, Huang S, Milne R
Br J Cancer 2002 Feb 12;86(4):501-5. doi: 10.1038/sj.bjc.6600135. PMID: 11870527 Free PMC Article

See all (7)

MedGen

National Center for Biotechnology Information

Send to:

Recurrent Malignant Glioma

Definition

Term Hierarchy

Professional guidelines

PubMed

Recent clinical studies

Etiology

Diagnosis

Therapy

Prognosis

Clinical prediction guides

Recent systematic reviews

Supplemental Content

Table of contents

Practice guidelines

Related information

Recent activity